Pacira BioSciences, Inc.
$ 23.98
-0.87%
04 Dec - close price
- Market Cap 1,086,922,000 USD
- Current Price $ 23.98
- High / Low $ 24.34 / 23.90
- Stock P/E 51.47
- Book Value 16.93
- EPS 0.47
- Next Earning Report 2026-02-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.03 %
- 52 Week High 27.64
- 52 Week Low 18.17
About
Pacira BioSciences, Inc. (PCRX) is a pioneering biopharmaceutical company headquartered in Parsippany, New Jersey, dedicated to transforming pain management through innovative non-opioid therapies and regenerative health solutions. By focusing on advanced pain management alternatives, Pacira addresses the critical need for effective solutions that reduce opioid reliance, thereby enhancing patient outcomes and supporting healthcare professionals' practices. With a robust pipeline and a strong commitment to research and development, the company is strategically positioned to lead the evolution of pain management, making significant contributions to patient care and the broader healthcare ecosystem.
Analyst Target Price
$30.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-03 | 2023-02-28 |
| Reported EPS | 0.7 | -0.11 | 0.62 | 0.91 | 0.79 | 0.89 | 0.62 | 0.89 | 0.72 | 0.78 | 0.53 | 0.8 |
| Estimated EPS | 0.65 | 0.72 | 0.5971 | 0.8303 | 0.7 | 0.7 | 0.62 | 0.88 | 0.78 | 0.76 | 0.62 | 0.83 |
| Surprise | 0.05 | -0.83 | 0.0229 | 0.0797 | 0.09 | 0.19 | 0 | 0.01 | -0.06 | 0.02 | -0.09 | -0.03 |
| Surprise Percentage | 7.6923% | -115.2778% | 3.8352% | 9.5989% | 12.8571% | 27.1429% | 0% | 1.1364% | -7.6923% | 2.6316% | -14.5161% | -3.6145% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.882 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCRX
2024-09-25 08:15:00
DOMA Perpetual Capital Management sent a letter to the Board of Directors of Pacira Biosciences, urging them to immediately accelerate and increase its share buyback program. DOMA Perpetual, which controls about 4% of Pacira stock, believes the company's $400 million cash balance is inefficient and that the current stock price presents an extraordinary opportunity for shareholder return. They recommend completing the approved $150 million buyback before Q3 earnings and approving a new $300 million buyback in Q4, with further buybacks into 2025.
2024-08-26 10:25:00
This article discusses osteoarthritis and the innovative iovera° treatment for joint pain relief. iovera° is an FDA-cleared device that uses cryoneurolysis to freeze pain-causing nerves, offering relief for up to 90 days. It can be used for various joints affected by OA and is also beneficial for pain management before and after knee replacement surgery.
2024-08-12 13:37:00
Pacira BioSciences' shares plunged significantly after a U.S. District Court ruled its '495 patent for Exparel invalid, potentially allowing generic versions and impacting the company's main revenue source. The company is evaluating legal options, including an appellate review, while other infringement suits and forthcoming patents are still in play. Pacira's other pain-management products have not yet gained significant market traction.
2024-05-10 07:00:00
Pacira BioSciences, Inc. announced the pricing of $250.0 million in 2.125% convertible senior notes due 2029 in a private placement. The company expects to use the net proceeds to repurchase existing 0.750% Convertible Senior Notes due 2025, fund capped call transactions, and repurchase a portion of its common stock. These notes will mature on May 15, 2029, and will be convertible under certain conditions.
2024-05-08 00:00:00
A patent infringement trial between Pacira Biosciences Inc. and eVenus Pharmaceutical Laboratories Inc. concluded with closing arguments in a New Jersey federal courtroom. The case revolves around Pacira's accusation that eVenus infringed on its Exparel patent by seeking FDA approval for a generic version before the patent's expiration. Both sides presented extensive data, with eVenus using an "iceberg" metaphor to suggest critical data was withheld from Pacira's patent application, while Pacira maintained the legitimacy of its patent and clear infringement.
2022-12-19 18:06:32
This article highlights how Dr. Quintessa Miller in Destin, Florida, is improving mastectomy patients' recovery by using non-opioid pain management options. She incorporates EXPAREL into her Enhanced Recovery After Surgery (ERAS) protocols, significantly reducing the need for opioids post-operatively. The article emphasizes the importance of non-opioid options in mitigating the risks associated with the opioid epidemic while enhancing patient recovery.
